Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

FDA approves avelumab plus axitinib for renal cell carcinoma

The Food and Drug Administration (FDA) approved avelumab in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC).

Approval was based on JAVELIN Renal 101 (NCT02684006), a randomised, multi-centre, open-label trial of avelumab plus axitinib in 886 patients with untreated advanced RCC regardless of tumour PD-L1 expression.

Patients were randomised to receive either avelumab 10 mg/kg intravenous infusion every 2 weeks in combination with axitinib 5 mg twice daily orally or sunitinib 50 mg once daily orally for 4 weeks followed by 2 weeks off until radiographic progression or unacceptable toxicity.

The main efficacy endpoints were progression-free survival (PFS), assessed by blinded independent central review using RECIST 1.1, and overall survival (OS) in patients with PD-L1-positive tumours.

Secondary endpoints were PFS and OS in the total population.

A statistically significant improvement in PFS was demonstrated in patients with PD-L1-positive tumours (HR 0.61; 95% CI: 0.48, 0.79; p=0.0001).

A statistically significant improvement in PFS in the total population was also demonstrated (HR 0.69; 95% CI: 0.56, 0.84; p=0.0002) at interim analysis.

Median PFS in the total population was 13.8 months for patients on the avelumab plus axitinib arm and 8.4 months for patients who received sunitinib.

With a median overall survival follow-up of 19 months, OS data were immature with 27% deaths in the intent-to-treat population.

The most common adverse reactions of avelumab in combination with axitinib in ≥ 20 percent of patients with RCC were diarrhoea, fatigue, hypertension, musculoskeletal pain, nausea, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, rash, hepatotoxicity, cough, dyspnea, abdominal pain, and headache.

Grade 3 or 4 hepatotoxicity occurred in 9 percent of patients and resulted in in permanent discontinuation of avelumab or axitinib in 7 percent.

Major cardiac adverse events occurred in 7 percent of patients treated with the combination.

The recommended avelumab dose for advanced RCC is 800 mg as an intravenous infusion every 2 weeks in combination with axitinib 5 mg orally twice daily.

Source: The Food and Drug Administration (FDA)



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation